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Abstract: A high fructose intake exacerbates postprandial plasma triacylglycerol (TAG) concentration,
an independent risk factor for cardiovascular disease, although it is unclear whether this is due to
increased production or impaired clearance of triacylglycerol (TAG)-rich lipoproteins. We determined
the in vivo acute effect of fructose on postprandial intestinal and hepatic lipoprotein TAG kinetics and
de novo lipogenesis (DNL). Five overweight men were studied twice, 4 weeks apart. They consumed
hourly mixed-nutrient drinks that were high-fructose (30% energy) or low-fructose (<2% energy)
for 11 h. Oral 2H2O was administered to measure fasting and postprandial DNL. Postprandial
chylomicron (CM)-TAG and very low-density lipoprotein (VLDL)-TAG kinetics were measured
with an intravenous bolus of [2H5]-glycerol. CM and VLDL were separated by their apolipoprotein
B content using antibodies. Plasma TAG (p < 0.005) and VLDL-TAG (p = 0.003) were greater,
and CM-TAG production rate (PR, p = 0.046) and CM-TAG fractional catabolic rate (FCR, p = 0.073)
lower when high-fructose was consumed, with no differences in VLDL-TAG kinetics. Insulin was
lower (p = 0.005) and apoB48 (p = 0.039), apoB100 (p = 0.013) and non-esterified fatty acids (NEFA)
(p = 0.013) were higher after high-fructose. Postprandial hepatic fractional DNL was higher than
intestinal fractional DNL with high-fructose (p = 0.043) and low-fructose (p = 0.043). Fructose
consumption had no effect on the rate of intestinal or hepatic DNL. We provide the first measurement
of the rate of intestinal DNL in humans. Lower CM-TAG PR and CM-TAG FCR with high-fructose
consumption suggests lower clearance of CM, rather than elevated production, may contribute to
elevated plasma TAG, possibly due to lower insulin-mediated stimulation of lipoprotein lipase.
Keywords: chylomicrons; VLDL; kinetics; stable isotope tracers; apolipoprotein B100; apolipoprotein
B48; intestinal de novo lipogenesis; hepatic de novo lipogenesis; postprandial
1. Introduction
Elevated fasting or postprandial plasma triacylglycerol (TAG) has been shown to be an independent
risk factor for the development of cardiovascular disease (CVD) [1]. Raised postprandial TAG may result
from (i) overproduction of very low-density lipoproteins (VLDL), which are synthesised by the liver
and contain the higher molecular weight form of apolipoprotein (apo)B, apoB100; (ii) overproduction
of chylomicrons (CM), synthesised in the small intestine in response to dietary fat, which contain the
lower molecular weight form of apoB (apoB48); [iii] impaired clearance of CM and/or VLDL or [iv] a
combination of these processes.
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Diet is an important modifiable risk factor for CVD, and high consumption of the monosaccharide
fructose has been shown to increase both fasting [2,3] and postprandial TAG and apoB48 levels [4–6]
as well as fractional hepatic de novo lipogenesis (DNL) [7–9]. In the Syrian golden hamster, apoB48
production rate was higher following chronic fructose feeding (3 weeks) versus chow feeding [10].
In this study, primary enterocytes were isolated from the hamsters fed the two regimes and the synthesis
of de novo palmitate shown to be higher in enterocytes from fructose fed hamsters. This study supports
more recent findings, showing that fructose specifically stimulates the expression of genes for DNL and
apolipoprotein synthesis in small intestine enterocytes of mice, both in vitro and in vivo [11]. It is not
known whether isoenergetic fructose feeding can increase intestinal DNL or CM-TAG production rate
(PR) in humans. We investigated this using a validated constant-feeding methodology, to establish a
postprandial steady state, and a sequential three-step antibody immunoaffinity method [12,13], which
separates hepatic triacylglycerol-rich lipoproteins (TRL) from intestinal TRL. VLDL- and CM-TAG
kinetics were measured using an intravenous bolus of [2H5]-glycerol, and hepatic and intestinal DNL
were measured following oral administration of 2H2O.
2. Materials and Methods
The study protocol was approved by the University of Surrey Research Integrity and
Governance Office (reference: UEC/2015/020/FHMS) and the NHS Research Ethics Committee (REC
reference: 15/LO/0891; South East Coast—Surrey). The trial was registered on the ISRCTN registry
(ISRCTN93148765). Prior to initiation of study procedures, written informed consent was obtained
from all participants. Inclusion criteria: Caucasian men; age, 18–50 y; BMI, 25–32 kg/m2; <3 sessions of
aerobic exercise per week; weight stable for the previous 3 months (± 2.5 kg); normal haemoglobin
(13.5–17.5 g/dL); blood pressure < 160/100 mmHg. Exclusion criteria: >32 g of alcohol/day; current
smoker; fasting plasma glucose > 7 mmol/L; fasting plasma TAG > 4 mmol/L; prescribed lipid-lowering
medications; history of endocrinological, cardiovascular, gastrointestinal and liver diseases or renal
impairment; history of eating disorders, nausea or vomiting; relevant food allergies or intolerances
(e.g., fructose).
2.1. Experimental Design
This was an acute dietary study with a randomised crossover design, involving two postprandial
metabolic study days. On each study day, participants consumed isoenergetic high-fat drinks every
hour for 11 h (204 kcal per drink), which were either high (30%) or low (<2%) in fructose, in order
to elicit a steady postprandial TAG response. Following the first metabolic study day, participants
underwent a 4-week washout period before completing the second study visit.
Subjects were requested to avoid consuming alcohol and not to undertake any strenuous exercise
for 24 h prior to each metabolic study day. Subjects attended the Centre for Endocrinology, Diabetes
and Research (Cedar) at Royal Surrey County Hospital (Guildford, UK) on the afternoon before each
study day for a non-fasted blood sample, in order to determine their background level of plasma
2H2O and background enrichment of VLDL-TAG palmitate. At this visit, participants were given two
bottles containing loading doses (total of 3 g/kg of body water) of 2H2O (99.8%, Cambridge Isotope
Laboratories Inc., Tewksbury, MA, USA), to be consumed at 7 pm and 10 pm on the evening prior to
the study day. Subjects were also provided with a low-fat standardised meal (Big Soup, 500 g, Heinz)
to consume between 6 pm and 7 pm, as well as additional ad libitum drinking water (Nestlé Waters
UK Ltd., Buxton, London, UK) containing 4.5 g/L 2H2O, to consume following the first 2H2O loading
dose. Subjects were requested to consume no food or drinks other than those provided.
Metabolic study protocol (Figure 1): subjects were studied the morning after a 12 h fast. A cannula
was inserted into the antecubital vein of the forearm for blood sampling and a fasted blood sample
was taken (−240 min). Subjects then consumed either high- or low-fructose drinks every hour for the
following 11 h. Each test drink contained refined olive oil (13.4 mL; Napolina UK Ltd.), whey protein
powder (8.1 g; Myprotein.com, UK) and either fructose powder (15.0 g; Tate & Lyle, UK) for the
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high-fructose drink or maltodextrin powder (16.0 g; Myprotein.com, UK) as a complex carbohydrate
control for the low-fructose drink. Any added water contained 2H2O (5 g/L) and no added sugar
orange squash concentrate (Tesco Ltd., Welwyn Garden City, UK) as a flavouring. All test drinks were
made in batches <12 h before each study day and stored in sealed containers at 4 ◦C until required.
At 0 min, 4 h after the initiation of feeding, a postprandial steady state had been established and an
intravenous bolus (75 µmol/kg) of [2H5]-glycerol (30 mg/mL, 2.5 mL per vial, Pharmacy of Guy’s and St
Thomas’ NHS Foundation Trust, UK) was administered. Blood samples were taken at regular intervals
(Figure 1) for the isolation of TRL-TAG, the measurement of plasma glycerol enrichment, plasma 2H2O,
as well as glucose, plasma TAG, non-esterified fatty acids (NEFA) and serum insulin concentrations (at
hourly intervals). Blood samples were taken more frequently between 0 min and 180 min (at 5, 15, 30,
45, 60, 90, 120, 150 and 180 min) following administration of the [2H5]-glycerol bolus to allow plasma
glycerol enrichment to be determined, thus allowing kinetic modelling (see data analysis section)
of the incorporation of the glycerol tracer into TRL-TAG, CM-TAG and VLDL-TAG. As described
previously by Shojaee-Moradie et al. [12], glycerol enrichment in lipoprotein TAG increases with time,
peaking between 90 min and 120 min, and then decreases with time, and thus less frequent sampling
is required.
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Figure 1. Summary of the protocol for metabolic study days.
A fasted blood sample was taken (−240 min) before subjects consumed 11 identical high-fat
(55% energy) drinks, either high- (30% energy) or low-fructose (0% energy), every hour, for 11 h. Blood
samples were drawn at the times indicated with black arrows. At 0 min, an intravenous (i.v) bolus of
[2H5]-glycerol (75 µmol/kg) was administered to measure lipoprotein TAG kinetics.
Prior to each metabolic study day, participants completed a standardised food diary for the
previous 4 ays, in order to assess their energy and macronutrient intake. All food diaries were
analysed using the Nutrition Analysis Software Nutritics (version 5.025; Nutritics Ltd., Dublin, Ireland).
2.2. Labor t y Analyses
TAG-rich lipoproteins were separated fro plasma by flotation ultracentrifugation using an
LE80-K ultracentrifuge with a type 50.4 Ti fixed-angle rotor (Beckman Coulter Inc., Pasadena, CA,
USA), to obtain particles with a Svedberg flotation rate (Sf) > 20 [14]. VLDL and CM particles
were isolated from the TRL samples by a sequential immunoaffinity binding method as previously
described [12,13]. Three monoclonal antibodies to apoB100 (4G3, 5E11 and BSol16, Heart Institute,
University of Ottawa, Ottawa, ON, Canada), coupled separately to protein G Sepharose 4 Fast flow
(Amersham, UK), were used sequentially. The bound apoB100 co taining VLDL fractions from
each f the three sequential affinity chromatography steps were combined. The unbound apoB48
containing CM fractions were also c mbined. TAG in VLDL a d CM fractions were extracted, purified
by thin layer chromatography and hydrolysed in the presence of 3% hydrochloric acid:methanol
to yield separate layers containing glycerol from TAG (TAG-glycerol) and fatty acid methyl esters
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(FAME). The layer containing TAG-glycerol and also plasma samples (the latter for plasma free
glycerol analysis) were deproteinied and purified by ion-exchange chromatography. Freeze-dried
glycerol was derivatized with N-tert-Butyldimethylsilyl-N-methyltrifluoroacetamide (MTBSTFA)
to form the tert-butyldimethylsilyl (TBDMS) glycerol derivative and enrichment was measured by
gas chromatography-mass spectrometry (GCMS) (Agilent 5975) in electron ionization mode. Ions
monitored were m/z 377.4 and m/z 382.4 (m + 5) [15]. The [2H]-enrichment of the palmitate methyl ester
(PAME) generated from the hydrolysis and derivatisation of TAG was measured to determine hepatic
DNL (VLDL fraction) and intestinal DNL (CM fraction). Samples were analysed with a Thermo Trace
1310 GC coupled to a Delta V Advantage isotope ratio mass spectrometer, with a GC Isolink II interface
(Thermo Scientific, Hemel Hempstead, UK). Plasma samples were analysed in duplicate for 2H2O
enrichment with a Gasbench II inlet system and Delta V Advantage isotope ratio mass spectrometer.
Platinum catalyst rods were added to the plasma samples to generate hydrogen gas from the plasma
water. Sample tubes were capped and flushed (100 mL/min) with the equilibration gas, 2% H2 in
helium and equilibrated for 6 h at 22.5 ◦C. Isotopic enrichment was measured relative to laboratory
standards previously calibrated against the international standards Vienna Standard Mean Ocean
Water 2 (VSMO2), Standard Light Arctic Precipitation (SLAP2) and Greenland Ice Sheet Precipitation
(GISP) (International Atomic Energy Agency, Vienna, Austria). A series of four QCs (quality controls)
of different enrichments were run with each set of samples, all of which had a mean CV < 2%.
Concentrations of fasting and postprandial plasma non-esterified fatty acids (NEFA), plasma
TAG and TRL-TAG were measured by enzymatic assay (ABX, Shefford, UK) using a Cobas MIRA
(Roche, Welwyn Garden City, UK). Serum insulin concentrations were measured by radioimmunoassay
(Millipore Corporation, Billerica, MA, USA). ApoB48 was measured by ELISA (AKHB48, Shibayagi
Corporation, Japan) and apoB-100 by an in-house ELISA.
2.3. Data Analysis
All tracer enrichments were expressed as tracer/tracee ratio (TTR). Using compartmental modelling,
CM-TAG and VLDL-TAG fractional catabolic rate (FCR) and production rate (PR) were analysed [16].
A single-pool model was used to describe CM-TAG and VLDL-TAG kinetics with plasma glycerol as
precursor pool using the SAAM II program (SAAM Institute, Seattle, WA, USA). The model represents
the kinetics of the TTR profiles, which change as labelled glycerol is removed from plasma and
incorporated into the TAG fractions. Plasma glycerol kinetics were described by a sum of three
exponentials representing a three-compartment model. The incorporation of glycerol into VLDL by the
liver and by the intestine is subject to a time delay which was described by a five-compartment chain.
The model assumes a steady-state of native (unlabelled) glycerol throughout the experimental
period. VLDL-TAG and CM-TAG production rates were calculated as the product of VLDL-TAG
fractional catabolic rate (FCR) and CM-TAG FCR and their respective TAG pools. VLDL and CM-TAG
pools were calculated from VLDL and CM-TAG concentration and plasma volume, as previously
described [17].
The percent contribution of hepatic DNL to VLDL-TAG PR and intestinal DNL to CM-TAG
PR (fractional DNL) was calculated from the deuterium enrichment in the palmitate of VLDL and
CM-TAG, respectively, and in plasma water, as previously described [18]. The absolute contribution of
DNL (mg/d) to postprandial VLDL-TAG PR and CM-TAG PR was estimated as:
DNL contribution to VLDL-TAG PR (g/d) =% hepatic DNL × VLDL-TAG PR (g/d) × 100.
DNL contribution to CM-TAG PR (g/d) =% intestinal DNL × CM-TAG PR (g/d) × 100.
2.4. Statistical Analysis
All time course variables were analysed using a linear mixed model to compare mean steady-state
postprandial values (0–420 min) from high- and low-fructose visits. The model included estimation
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of the main effects for visit (visit 1 or visit 2), treatment (high- or low-fructose drink) and time
(0 to 420 min), with visit-by-treatment and time-by-treatment interactions. Baseline fasting values
(−240 min, fasted value) were added as a covariate. All variables were checked visually for normality
of distribution using Q-Q plots and any non-normally distributed variables were log-transformed
prior to analysis. One-way repeated measures ANOVA analysis was also performed for plasma TAG,
CM-TAG and VLDL-TAG values for steady-state time points (0–420 min), to confirm the presence of
a constant postprandial TAG concentration, necessary for kinetic calculations. Differences between
fasted and mean postprandial values for high- and low-fructose visits were analysed by Wilcoxon
signed-rank test. For fasted and postprandial fractional DNL data, correlations between intestinal and
hepatic DNL values were compared by Spearman’s correlation analysis. All statistical analyses were
performed using SPSS version 24 (IBM Corp, Armonk, NY, USA). For all tests, p < 0.05 was considered
statistically significant. Data are mean ± SEM.
3. Results
3.1. Participant Characteristics
Five subjects were recruited in accordance with the inclusion and exclusion criteria (mean ± SEM
age 32 ± 3 y; body weight 93.1 ± 3.2 kg; BMI 27.3 ± 0.9 kg/m2; plasma glucose 4.8 ± 0.3 mmol/L; plasma
TAG 1.28 ± 0.40 mmol/L).
Analysis of the diet diaries showed there were no significant differences in the subjects’ diet in the
four days preceding the high- and low-fructose visits for any of the macronutrients analysed, including
total dietary sugars, sucrose, glucose and fructose (data not shown). Mean fasting (−240 min) values
were not significantly different between high-fructose and low-fructose study visits for plasma TAG or
other metabolic measurements (Table 1).
Table 1. Fasting and mean postprandial (0–420 min) plasma glucose, serum insulin, plasma NEFA, TRL
apoB48 and TRL apoB100 in response to high- and low-fructose drinks. Values are mean ±SEM (n = 5).
High-Fructose Low-Fructose p-Value
Fasting glucose (mmol/L) 4.63 ± 0.26 4.76 ± 0.12 0.495
Fasting insulin (pmol/L) 65.6 ± 12.4 85.4 ± 20.0 0.063
Fasting NEFA (mmol/L) 0.69 ± 0.17 0.81 ± 0.13 0.492
Fasting apoB48 (mg/L) 1.2 ± 0.5 1.1 ± 0.5 0.860
Fasting apoB100 (mg/L) 18.1 ± 5.4 19.7 ± 7.5 0.812
Fasting Hepatic % DNL 2.26 ± 0.65 1.30 ± 0.51 0.269
Fasting Intestinal % DNL 1.75 ± 0.46 1.27 ± 0.42 0.284
Postprandial glucose (mmol/L) 5.21 ± 0.09 5.67 ± 0.23 <0.005
Postprandial insulin (pmol/L) 113.0 ± 16.5 171.5 ± 31.5 <0.005
Postprandial NEFA (mmol/L) 0.38 ± 0.06 0.35 ± 0.05 0.013
Postprandial apoB48 (mg/L) 5.48 ± 2.11 3.35 ± 0.79 0.039
Postprandial apoB100 (mg/L) 23.89 ± 4.66 19.19 ± 6.26 0.013
Hepatic postprandial % DNL 4.36 ± 1.85 2.21± 1.36 0.308
Intestinal postprandial % DNL 2.33 ± 1.05 1.08 ± 0.24 0.100
Abbreviations: apoB48, apolipoprotein B48; apoB100, apolipoprotein B100; DNL, de novo lipogenesis; NEFA,
non-esterified fatty acids; TRL, triacylglycerol-rich lipoproteins. High- and low-fructose treatments were compared
using a paired-samples t-test (significant values p < 0.05 indicated in bold).
3.2. Postprandial Lipoprotein Kinetics
Postprandial plasma TAG (Figure 2; p < 0.005) and VLDL-TAG (Figure 3; p = 0.003) concentrations
were higher in response to high-fructose feeding, compared to low-fructose feeding, although no
significant effect of fructose was detected for TRL-TAG (Figure 2; p = 0.145) or CM-TAG concentrations
(Figure 3; p = 0.292). Mean postprandial total apoB (p = 0.029) (data not shown), apoB48 (p = 0.039)
and apoB100 (p = 0.013) (Table 1) were all significantly higher during high-fructose feeding.
Nutrients 2020, 12, 1781 6 of 13Nutrients 2020, 12, x FOR PEER REVIEW 8 of 14 
 
 
Figure 2. Mean plasma TAG (A) and TRL-TAG (B) responses to high- or low-fructose drinks. Subjects 
consumed high-fructose (white circles) or low-fructose (black circles) drinks every hour (black 
arrows) from fasted (−240 min) to achieve a steady postprandial state (0 min; grey arrow), at which 
time a bolus of [2H5]-glycerol was administered to measure lipoprotein TAG kinetics (0–420 min). 
Data are mean ± SEM. Time course responses were analysed by a linear mixed model to determine 
the treatment effect: for plasma TAG P < 0.005; for TRL-TAG P = 0.145 (NS). TAG, triacylglycerol; 
TRL, triacylglycerol-rich lipoproteins. 
Figure 2. Mean plasma TAG (A) and TRL-TA (B) responses to high- or lo -fructose drinks. Subjects
consu ed t s (white circles) or low-fructose (black circles) drinks every hour (black arrows)
f om fasted (−240 min) to achieve a steady postprandial state (0 min; grey arrow), at hich time a
bolus of [2H5]-glycerol was administered to measure lipoprotein TAG kinetics (0–420 min). Data are
me n ± SEM. Time cours respons wer analysed by a linear mixed model to determine the
tr atment effect: for plasma TAG p < 0.005; for TRL-TAG p = 0.145 (NS). TAG, triacylglycerol; TRL,
triacylglycerol-rich lipoproteins.
Nutrients 2020, 12, 1781 7 of 13Nutrients 2020, 12, x FOR PEER REVIEW 9 of 14 
 
 
Figure 3. CM-TAG (A) and VLDL-TAG (B) responses to high- or low-fructose drinks. Subjects 
consumed high-fructose (white circles) or low-fructose (black circles) drinks every hour (black 
arrows) from fasted (−240 min) to achieve a steady postprandial state (0 min; grey arrow), at which 
time a bolus of [2H5]-glycerol was administered to measure lipoprotein TAG kinetics (0–420 min). 
Data are mean ± SEM (n = 5). Time course responses were analysed by a linear mixed model to 
determine the treatment effect: for CM-TAG; P = 0.292 (NS); for VLDL-TAG P = 0.003. CM, 
chylomicron; TAG, triacylglycerol; VLDL, very low-density lipoprotein. 
3.3. De Novo Lipogenesis 
Fasted fractional intestinal DNL ranged from 0.40 to 2.67% across both high-fructose and low-
fructose study visits, values which were quantitatively similar to those for hepatic DNL (range 0.30 
to 4.17%). Postprandial fractional intestinal DNL showed little change from fasting, whereas hepatic 
DNL rose with feeding (an effect that was more marked with high fructose feeding, although not 
statistically significant). In the postprandial state, hepatic fractional DNL was significantly higher 
than intestinal fractional DNL, during both high and low fructose feeding (both P = 0.043). This 
difference was lost when expressed as the rate of DNL (mg/d) (Table 2). 
It was noted that the within subject values for intestinal and hepatic fractional DNL were 
quantitatively similar during both high- and low-fructose visits. Due to the lack of any significant 
effect of fructose feeding, data were pooled (n = 10) and analysed by Spearman’s correlation analysis 
(data not shown), which revealed a highly significant within-subject correlation between intestinal 
Figure 3. CM-TAG (A) and VLDL-TAG (B) responses to high- or low-fructose drinks. Subjects
consumed high-fructose (white circles) or low-fructose (black circles) drinks every hour (black arrows)
from fasted (−240 min) to achieve a steady postprandial state (0 min; grey arrow), at which time a
bolus of [2H5]-glycerol was administered to measure lipoprotein TAG kinetics (0–420 min). Data are
mean ± SEM (n = 5). Time course responses were analysed by a linear mixed model to determine
the treatment effect: for CM-TAG; p = 0.292 (NS); for VLDL-TAG p = 0.003. CM, chylomicron; TAG,
triacylglycerol; VLDL, very low-density lipoprotein.
Lipoprotein TAG kinetic analysis revealed a significantly lower mean CM-TAG production rate
(PR; p = 0.046) in response to high- versus low-fructose drinks (Table 2), which was accompanied by
a lower CM-TAG FCR, although this difference did not quite attain statistical significanc (p = 0.07).
Despit the higher postprandial VLDL-TAG concentration, there wer no significant differences in
mean VLDL-TAG PR or FCR between study visits.
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Table 2. Postprandial CM-TAG and VLDL-TAG kinetics and DNL in response to high- and low-fructose
drinks. Values are mean ± SEM (n = 5).
High-Fructose Low-Fructose p-Value
CM-TAG PR (mg/kg/d) 152.9 ± 76.6 375.93 ± 68.8 0.046
CM-TAG FCR (pools/d) 7.44 ± 4.01 21.69 ± 7.60 0.073
CM-TAG PS (mg) 2976 ± 1060 2247 ± 653 0.367
Intestinal DNL (mg/d) 216 ± 78 318 ± 68 0.225
VLDL-TAG PR (mg/kg/d) 81.03 ± 19.57 68.43 ± 12.18 0.641
VLDL-TAG FCR (pools/d) 10.35 ± 3.50 12.21 ± 2.78 0.254
VLDL-TAG PS (mg) 1042 ± 460 634 ± 217 0.072
Hepatic DNL (mg/d) 476 ± 310 165 ± 64 0.138
High- and low-fructose treatments were compared using a paired-samples t-test (significant values p < 0.05 indicated
in bold). Abbreviations: CM, chylomicron; DNL, de novo lipogenesis; FCR, fractional catabolic rate; PR, production
rate; PS, pool size.
3.3. De Novo Lipogenesis
Fasted fractional intestinal DNL ranged from 0.40 to 2.67% across both high-fructose and
low-fructose study visits, values which were quantitatively similar to those for hepatic DNL (range 0.30
to 4.17%). Postprandial fractional intestinal DNL showed little change from fasting, whereas hepatic
DNL rose with feeding (an effect that was more marked with high fructose feeding, although not
statistically significant). In the postprandial state, hepatic fractional DNL was significantly higher than
intestinal fractional DNL, during both high and low fructose feeding (both p = 0.043). This difference
was lost when expressed as the rate of DNL (mg/d) (Table 2).
It was noted that the within subject values for intestinal and hepatic fractional DNL were
quantitatively similar during both high- and low-fructose visits. Due to the lack of any significant
effect of fructose feeding, data were pooled (n = 10) and analysed by Spearman’s correlation analysis
(data not shown), which revealed a highly significant within-subject correlation between intestinal
and hepatic fractional DNL values in both the fasted (ρ = 0.939, p < 0.0001) and postprandial states
(ρ = 0.818, p = 0.004), indicating a strong association between these two parameters.
3.4. Other Postprandial Measurements
Mean postprandial plasma glucose (p < 0.005) and serum insulin (p = 0.005) concentrations
were significantly lower, and plasma NEFA remained significantly higher (p = 0.013), when subjects
consumed high-fructose drinks, compared to low-fructose drinks.
4. Discussion
Plasma TAG was higher and CM-TAG PR and FCR were lower with acute high-fructose feeding
compared to low-fructose feeding. This suggests lower clearance of CM, rather than elevated
production, contributed to the elevated plasma TAG concentration. This study also provides the first
known estimate of the rate of intestinal DNL undertaken in human subjects and thus adds to the limited
existing evidence demonstrating a DNL capability within enterocyte cells of the small intestine [19,20].
The increase in plasma TAG with high fructose feeding is in agreement with previous studies
comparing acute feeding with fructose, versus either complex carbohydrate or glucose, in both men and
women with BMIs ranging from normal to obese [6,21,22]. The higher VLDL-TAG with fructose feeding
in our study has also been reported previously [22]. However, lipoprotein kinetic analysis in our study
failed to explain the potential mechanisms for this greater VLDL-TAG excursion. Neither postprandial
VLDL-TAG PR nor FCR were significantly different between the two feeding regimes, probably due
to the small number of subjects and the large inter-individual variation for these measurements.
It has been shown previously in seven healthy men that an intraduodenal co-infusion of fructose
and intralipid (a fat emulsion intended for use in a pharmacy admixture programme) increased TRL
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apoB100 PR, with no effect on FCR, compared to co-infusion of glucose and lipid [23], but VLDL-TAG
PR was not measured.
Although CM-TAG tended to be higher during high- versus low-fructose feeding, this difference
did not reach statistical significance. Other studies have reported on the effect of fructose feeding on
CM-TAG, measured as the Sf > 400 fraction, obtained via ultracentrifugation [9,19,20,22]. This fraction
contains much larger lipoprotein particles than the Sf > 20 fraction isolated in the current study,
and fails to isolate smaller CM, which reside in the Sf 60–400 density range during the later postprandial
phase [24]. While in three of these studies, fructose feeding did not have a significant effect on
Sf > 400 TAG concentration, Chong et al. (2007) reported a significantly higher CM-TAG after a
fructose bolus, compared with a glucose bolus, during the later post-prandial phase [22]. The finding of
a lower CM-TAG PR and FCR during high-fructose feeding in this study suggests the higher CM-TAG
concentration was due to reduced clearance. Since mean postprandial serum insulin concentrations
were lower during high fructose feeding, this may have resulted in lower insulin-mediated stimulation
of lipoprotein lipase [25,26], thus causing a greater accumulation of CM and VLDL lipoprotein
particles in the postprandial state. This is the first study to measure the specific effect of fructose on
CM-TAG kinetics.
Plasma apoB48 concentrations were significantly higher with fructose feeding, indicating greater
numbers of CM particles, including CM remnants. This finding is in agreement with Xiao et al.
(2013), who reported increased TRL-apoB48 concentrations during intraduodenal infusion of fructose
compared with glucose infusion [23]. This study also found apoB48 FCR and PR to be lower with
intraduodenal fructose than with glucose, suggesting that higher mean postprandial plasma apoB48
concentrations in our study may also be due to lower FCR [23].
The use of antibodies in the current study to separate TRL lipoproteins of intestinal and hepatic
origin, according to their specific apoB content, provides a precise measurement of both intestinal and
hepatic DNL. A recent study also used antibodies to separate chylomicrons and VLDL, and measured
intestinal postprandial fractional DNL [27]. Measurements in four subjects ranged from 1–4% intestinal
DNL; values that were similar to the current study.
To our knowledge, the only other human studies of intestinal DNL were in normal weight
(21.9 kg/m2; 4 females, 4 males) [20] and obese (44.2 kg/m2; 5 females, 3 males) [19] subjects given
mixed-nutrient meals. In both studies, [U-13C]-fructose given as part of the test meals was recovered
as [13C]-palmitate in TAG in the Sf > 400 TRL fraction, which is typically assumed to represent CM
lipoproteins of intestinal origin. It was claimed that this showed fructose may be utilised as a lipogenic
substrate by enterocyte cells. However, the authors were unable to quantify the amount of de novo
palmitate synthesised from fructose, as the stable isotope tracer enrichment in the acetyl-CoA precursor
pool could not be determined. In addition, the Sf > 400 TRL fraction would have been contaminated
with VLDL, as demonstrated by Jones et al. (2019) [27]. It is also possible in the above mentioned
studies using [U-13C]-fructose that inclusion of male and female subjects may limit the ability to make
comparisons with our study, in which only male subjects were studied.
Although animal studies have shown higher intestinal DNL with fructose feeding compared
with control feeding, we did not find this in the current study. In Syrian golden hamsters, an animal
model of insulin resistance, the incorporation of radio-labelled [3H]-acetate into de novo fatty acids
was three-fold greater when animals were fed a high-fructose diet (60% energy) for 3 weeks, relative to
those fed a control diet of chow [10]. This may be the consequence of chronic feeding, rather than the
acute fructose feeding used in our study, the presence of insulin resistance, or a different sensitivity to
fructose (for use as a lipogenic substrate) between hamsters and humans.
A number of human studies have reported that chronic fructose consumption stimulates hepatic
DNL [9,28], and that higher fructose doses induce a higher percentage hepatic DNL in a dose-dependent
manner [7]. Hepatic DNL has also been shown to be higher in subjects following fructose feeding,
than when consuming the same number of calories as either complex carbohydrate [8] or glucose [29].
However, the measurement of DNL in the Sf 60–400 fraction, without antibody separation of CM
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and VLDL, could have led to cross contamination with smaller CM and CM remnants, as shown by
Jackson et al. (2002) [24], and may have accounted for a proportion of the de novo lipids. The failure to
demonstrate an increase in hepatic DNL with acute fructose feeding in the current study may be due
to the small number of subjects, the large inter-individual variation between subjects, or the need for
chronic feeding to stimulate upregulation of key enzymes in the lipogenic pathway (e.g., acetyl-CoA
carboxylase). It is also possible that fructose feeding without glucose may have directed part of
the ingested fructose load away from glyceroneogenesis (to form glycerol-3-phopsphate that may
be utilised for de novo TAG synthesis) and/or DNL, and towards formation of glucose via the
gluconeogenic pathway.
Other limitations of the current study include the large doses of fructose (165 g/d), maltodextrin
(176 g/d) and fat (135 g/d) administered to participants during metabolic study visits, which would
typically be considered supra-physiological, and may only feasibly be consumed occasionally by a
small proportion of the population, who are among the highest consumers. It should also be noted
that fructose in the diet is typically co-ingested with glucose, and often in approximately equimolar
amounts within sucrose (bound to glucose) or high-fructose corn syrup (as a free monosaccharide).
Therefore, ingestion of a large amount of fructose in isolation is less physiologically feasible than in the
presence of a proportion of carbohydrate as glucose.
Although the subjects had fasting metabolic measurements (including fasting glucose and plasma
TAG) taken at the beginning of each metabolic study visit, which did not reveal any significant changes
between visits, it is possible that alterations in their diet, physical activity levels and other lifestyle
factors, during the four-week washout period, may have influenced their responses to the high- and
low-fructose drinks. While the four-day food diaries indicated there were no differences in the subjects’
diet immediately prior to each visit, this did not necessarily capture their true habitual diet, due to
potential issues of under-reporting or changing the foods consumed during this period to appear more
acceptable [30].
Lastly, only a single ultracentrifugation step was used to isolate lipoproteins residing in the Sf > 20
range, meaning it was not possible to differentiate between VLDL1 (Sf 60–400) and VLDL2 (Sf 20–60)
lipoprotein subclasses. Our laboratory has previously shown a difference in VLDL production in
response to a high sugar diet (26% energy) in men with non-alcoholic fatty liver disease (NAFLD),
compared to low liver fat control subjects [31]. While in control subjects a high sugar diet channelled
hepatic TAG toward a higher production of VLDL1-TAG, patients with NAFLD exhibited a greater
production of VLDL2-TAG. It is possible that additional separation of these two lipoprotein subclasses
in the current study may have revealed differences in their regulation in response to a high fructose load,
providing additional insight into the metabolic effects of fructose on postprandial TAG metabolism.
In summary, our findings indicate that intestinal and hepatic DNL made only a minor contribution
to CM-TAG and VLDL-TAG production rate, respectively, in healthy subjects during high-dose acute
fructose feeding. However, the highly significant within-subject correlations between intestinal and
hepatic DNL, both in the fasted and postprandial states, suggests that intestinal DNL is upregulated in
concert with hepatic DNL. If a similar relationship between rates of hepatic and intestinal DNL occurs
in subjects with insulin resistance, the intestine may make a significant contribution to plasma TAG
levels, as hepatic DNL is enhanced several-fold in these individuals [32,33]. Further studies are needed
to confirm this.
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